Showing results (71-80 of 78) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
Clinical Genitourinary Cancer|June 8, 2019
Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials ConsortiumChanning J Paller, Emmanuel S Antonarakis, Tomasz M Beer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 18, 2025
Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate CancerMatthew D Galsky, Karen A Autio, Christopher R Cabanski, et al.
Prostate Cancer and Prostatic Diseases|August 12, 2024
Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 studyJulie N Graff, Christopher J Hoimes, Winald R Gerritsen, et al.
JCO Oncology Practice|September 28, 2020
Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTCBrittany M Szymaniak, Lauren A Facchini, Veda N Giri, et al.
European Urology Open Science|December 22, 2021
Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical ProstatectomyKaren A Autio, Emmanuel S Antonarakis, Tina M Mayer, et al.
Prostate Cancer and Prostatic Diseases|February 27, 2019
MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancerNicholas G Nickols, Ramin Nazarian, Shuang G Zhao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2025
National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design ConsiderationsDavid J Einstein, Melissa L Abel, Jeanny B Aragon-Ching, et al.
Cancer Discovery|December 9, 2024
Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate CancerLisa N Chesner, Fanny Polesso, Julie N Graff, et al.
Pageof 8